Summary
Factors reflecting two major aspects of tumour biology, invasion (urokinase-type plasminogen activator (uPA), plasminogen activator inhibiter (PAI-1), cathepsin D) and proliferation (S-phase fraction (SPF), Ki-67, p53, HER-2/neu), were assessed in 125 node-negative breast cancer patients without adjuvant systemic therapy. Median follow-up time was 76 months. Antigen levels of uPA, PAI-1 and cathepsin D were immunoenzymatically determined in tumour tissue extracts. SPF and ploidy were determined flow-cytometrically, Ki‴-67, p53, and HER-2/neu immunohistochemically in adjacent paraffin sections. Their prognostic impact on disease-free (DFS) and overall survival (OS) was compared to that of traditional factors (tumour size, grading, hormone receptor status). Univariate analysis determined PAI-1 (P < 0.001), uPA (P = 0.008), cathepsin D (P = 0.004) and SPF (P = 0.023) as significant for DFS. All other factors failed to be of significant prognostic value. In a Cox model, only PAI-1 was significant for DFS (P < 0.001, relative risk (RR) 6.2). In CART analysis for DFS, the combination of PAI-1 and uPA gave the best risk group discrimination. For OS, PAI-1, cathepsin D, tumour size and ploidy were statistically significant in univariate, but PAI-1 was the only independently significant factor in Cox analysis (P < 0.001, RR 8.9). In particular, this analysis shows that PAI-1 is still a strong and independent prognostic factor in node-negative breast cancer after extended 6-year median follow-up.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bagwell, C. B., Mayo, S. W., Whetstone, S. D., Hitchcox, S. A., Baker, D. R., Herbert, D. J., Weaver, D. L., Jones, M. A. & Lovett, E. J. (1991). DNA histogram debris theory and compensation. Cytometry 12: 107–118.
Benraad, T. J., Geurts-Moespot, J., Grøndahl-Hansen, J., Schmitt, M., Heuvel, JJTM, deWitte, J. H., Foekens, J. A., Leake, R. E., Brünner, N. & Sweep, C. G. J. (1996). Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A: 1371–1381.
Blankenstein, M. A. (1997). Biochemical assessment of tissue prognostic factors in breast cancer. Breast 6: 31–37.
Bouchet, C., Spyratos, F., Martin, P. M., Hacène, K., Gentile, A. & Oglobine, J. (1994). Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398–405.
Breiman, I., Friedman, J., Olshen, R. & Stone, C. (1984). Classification and Regression Trees. Chapman and Hall: New York
Brown, R. W., Allred, C. D., Clark, G. M., Osborne, C. & Hilsenbeck, S. (1996). Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585–592.
Clark, G. M. (1996). Prognostic and predictive factors. In Diseases of the Breast. Harris JR, Lippmann ME, Morrow M and Hellmann S (eds), pp. 461–485. Lippincott-Raven: Philadelphia
Clark, G. M. & McGuire, W. (1988). Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20–25.
Cox, D. R. (1972). Regression models and life-tables. J R Stat Soc (B) 34: 187–200.
Danø, K., Andreasen, P. A., Grøhndahl-Hansen, J., Kristensen, P., Nielsen, L. & Skriver, L. (1985). Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139–266.
Dettmar, P., Harbeck, N., Thomssen, C., Pache, L., Ziffer, P., Fizi, K., Jänicke, F., Nathrath, W., Schmitt, M., Graeff, H. & Höfler, H. (1997). Prognostic impact of the proliferation associated factors Ki-67 and S-phase in node-negative breast cancer using MIB1 immunostaining and flowcytofluorometric S-phase determination. Br J Cancer 75: 1525–1533.
D’hautcourt, J. L. & Spyratos, F. & Chassevent A., on behalf of the Association Francaise de Cytometrie (1996). Quality control study by the French cytometry association on flow cytometric DNA content and S-phase fraction (S%). Cytometry (Comm Clin Cytometry) 26: 32–39.
Duffy, M. J., Reilley, D., O’Sullivan, C., O’Higgins, N., Fennelly, J. N. & Andreasen, P. (1990). Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829.
Elston, C. W. & Ellis, I. O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410.
Fernö, M., Bendahl, P. O., Borg, A., Brundell, J., Hirschberg, L., Olsson, H. & Killander, D. (1996). Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793–801.
Foekens, J. A., Schmitt, M., van Putten, W. L. J., Peters, H. A., Kramer, M. D., Jänicke, F. & Klijn, J. G. M. (1994). Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncology 12: 1648–1658.
Gasparini, G., Boracchi, P., Verderio, P. & Bevilacqua, P. (1994). Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57: 822–829.
Graeff, H., Wilmanns, W., Jänicke, F., Sauer, H. & Classen, S. (1997). Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Onkologe 3: 409–412.
Grøhndahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brünner, N., Mouridsen, H. T., Danø, K. & Blichert-Toft, M. (1993). High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521.
Grøhndahl-Hansen, J., Christensen, I. J., Briand, P., Pappot, H., Mouridsen, H. T., Blichert-Toft, M., Danø, K. & Brünner, N. (1997a). Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 3: 233–239.
Grøhndahl-Hansen, J., Hilsenbeck, S. G., Christensen, I. J., Clark, G. M., Osborne, C. K. & Brünner, N. (1997b). Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153–163.
Harbeck, N., Yamamoto, N., Moniwa, N., Schüren, E., Ziffer, P., Dettmar, P., Höfler, H., Schmitt, M. & Graeff, H. (1994). Flow cytometric DNA analysis in primary breast cancer: technical pitfalls and clinical applications. In Prospects in Diagnosis and Treatment of Cancer, Schmitt M, Graeff H and Jänicke F (eds), pp. 63–74. Elsevier Science: Amsterdam
Harbeck, N., Dettmar, P., Thomssen, C., Henselmann, B., Kuhn, W., Ulm, K., Jänicke, F., Höfler, H., Graeff, H. & Schmitt, M. (1998). Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 18: 2187–2198.
Harris, J. R., Lippman, M. E., Veronesi, U. & Willett, W. (1992). Medical progress: breast cancer (third of three parts). N Engl J Med 327: 473–490.
Hiddemann, W., Schumann, J., Andreeff, M., Barlogie, B., Herman, C. J., Leif, R. C., Mayall, B. H., Murphy, R. F. & Sandberg, A. A. (1984). Convention on nomenclature for DNA cytometry. Cytometry 5: 445–446.
Hilsenbeck, S. G. & Clark, G. M. (1996). Practical p-value adjustment for optimally selected cutpoints. Stat Med 15: 103–112.
Kaplan, E. L. & Meier, P. (1958). Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W. & Graeff, H. (1990). Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69–78.
Jänicke, F., Schmitt, M. & Graeff, H. (1991). Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17: 303–312.
Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H. & Graeff, H. (1993). Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195–208.
Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A. & Graeff, H. (1994a). Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527–2530.
Jänicke, F., Thomssen, C., Pache, L., Schmitt, M. & Graeff, H. (1994b). Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In Prospects in Diagnosis and Treatment of Cancer, Schmitt M, Graeff H and Jänicke F (eds), pp. 207–218. Elsevier Science: Amsterdam
Lauffenburger, D. (1996). Making connections count. Nature 383: 390–391.
McGuire, W. & Clark, G. M. (1992). Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326: 1756–1761.
Osborne, C. K. (1989). DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst 81: 1344–1345.
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R. & Flom, K. J. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894–2904.
Ravdin, P. M. (1993). Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219–226.
Rochefort, H. (1992). Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A: 1780–1783.
Schmitt, M., Jänicke, F. & Graeff, H. (1992). Tumor-associated proteases. Fibrinolysis 6: 3–26.
Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F. & Graeff, H. (1997a). Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thrombosis Haemostasis 78: 285–296.
Schmitt, M., Thomssen, C., Ulm, K., Seiderer, A., Harbeck, N., Höfler, H., Jänicke, F. & Graeff, H. (1997b). Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer Inst 76: 306–311.
Spyratos, F., Martin, P. M., Hacène, K., Romain, S., Andrieu, C., Ferrero-Poüs, M., Deytieux, S., LeDoussal, V., Tubiana-Hulin, M. & Brunet, M. (1992). Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266–1272.
Stefansson, S. & Lawrence, D. A. (1996). The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383: 441–443.
Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V. & Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273: 1551–1555.
Wenger, C. R., Beardslee, S., Owens, M. A., Pounds, G., Oldaker, T., Vendely, P., Pandian, M. R., Harrington, D., Clark, G. M. & McGuire, W. (1993). DNA ploidy, S-phase, and steroid receptors in more than 127 000 breast cancer patients. Breast Cancer Res Treat 28: 9–20.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Harbeck, N., Dettmar, P., Thomssen, C. et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80, 419–426 (1999). https://doi.org/10.1038/sj.bjc.6690373
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690373
Keywords
This article is cited by
-
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy
BMC Cancer (2019)
-
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
Breast Cancer Research (2014)
-
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
British Journal of Cancer (2010)
-
Relations du système plasminogène-plasmine et cancer
Oncologie (2010)
-
RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo
Breast Cancer Research and Treatment (2010)